Centers for Disease Control and Prevention Centers for Disease Control and Prevention CDC Home Search CDC CDC Health Topics A-Z site search
National Office of Public Health Genomics
Centers for Disease Control and Prevention
Office of Genomics and Disease Prevention
Site Search
 

HuGENet™: Fact sheets
chromosome


ALAD Genotype and Lead Toxicity
PUBLISHED: June 2001
AUTHORS: Samir Kelada and Erin Haynes

Download print version Link here to download free  Adobe Reader (12KB) 
Link to HuGE Review

line

squares ALAD GENE

The ALAD gene (chromosome 9q34) codes for δ-aminolevulinic acid dehydratase (ALAD), which catalyzes the asymmetric addition of two molecules of aminolevulinic acid (ALA) to form porphobilinogen -- the second step of heme synthesis.


squares PREVALENCE OF GENE VARIANTS

Eight ALAD variants have been described in the literature. Most attention has been paid to the G177C polymorphism, which yields two alleles, designated ALAD-1 and ALAD-2. The ALAD-2 allele contains a G ---> C transversion at position 177 of the coding region, resulting in the substitution of asparagine for lysine at amino acid 59. These two alleles determine three isozymes, designated 1-1, 1-2, and 2-2, all of which display similar activities but have different charges. The prevalence of the ALAD-2 allele ranges from 0 to 20 percent depending on the population. Generally, Caucasians have the highest frequency of ALAD-2 allele, with approximately 18 percent of the population being ALAD 1-2 heterozygotes and 1 percent being 2-2 homozygotes. Some studies used hospital-based study samples, while others used samples comprised of occupationally exposed individuals with relatively high blood lead levels.


squares DISEASE BURDEN

Studies have shown relations between ALAD G177C genotype and several features of lead toxicity. The evidence surrounding this ALADpolymorphism and lead poisoning can be summarized as follows: at high levels of exposure and in comparison to ALAD 1-1 genotype individuals, ALAD 1-2/2-2 genotype individuals have increased blood lead levels, lower concentrations of ALA in the plasma (ALAP), lower zinc protoporphyrin levels, lower cortical bone lead concentrations, higher concentrations of trabecular (spongy) bone lead, and lower amounts of chelatable lead (1,2,3, 5). These differences are only clearly evident at blood lead concentrations greater than 25 mg/dL. The data also suggest that lead exposed ALAD-1 homozygotes may be at greater risk of neurotoxicity than exposed ALAD 1-2 individuals, as ALAD-1 homozygotes have higher levels of ALAP. One study gave preliminary evidence that ALAD 1-2 individuals may have better neuropsychological performance than ALAD 1 homozygotes of similar lead exposure history (4).


squares
INTERACTIONS

Schwartz et al. (5) have evaluated interactions between ALAD and VDR, which codes for the Vitamin D Receptor. VDR is polymorphic and evidence suggests that alone it may influence the effect of lead exposure, but no evidence for gene-gene interaction was found.


squares
LABORATORY TESTS

Whereas early studies used an electrophoretic technique to distinguish ALAD protein variants (due to charge differences), most studies have used a PCR-based genotyping technique in which the polymorphic site is amplified and then cleaved with the MspI restriction enzyme. The cleavage products are then visualized on an agarose gel. There is complete concordance between the genotyping and phenotyping techniques.


squares
POPULATION TESTING

At this time, there is inadequate evidence to support population-based testing.


squares
REFERENCES

  1. Wetmur JG. Influence of the common human delta-aminolevulinate dehydratase polymorphism on lead body burden. Environ Health Perspect 1994;102 Suppl 3:215-9.
  2. Fleming DE, Chettle DR, Wetmur JG, et al. Effect of the delta-aminolevulinate dehydratase polymorphism on the accumulation of lead in bone and blood in lead smelter workers. Environ Res 1998;77(1):49-61.
  3. Schwartz BS, Lee BK, Stewart W, et al. delta-Aminolevulinic acid dehydratase genotype modifies four hour urinary lead excretion after oral administration of dimercaptosuccinic acid. Occup Environ Med 1997;54(4):241-6.
  4. Bellinger D, Hu H, Titlebaum L, et al. Attentional correlates of dentin and bone lead levels in adolescents. Arch Environ Health 1994;49:98-105.
  5. Schwartz BS, Lee B-L, Lee G-S, et al. Associations of Blood Lead, Dimercaptosuccinic Acid-Chelatable Lead, and Tibia Lead with Polymorphisms in the Vitamin D Receptor and d-Aminolevulinic Acid Dehydratase Genes. Environ Health Perspect 2000;108(10):949-54.

 

squares WEBSITES

  1. OMIM
  2. The National Institute for Occupational Safety and Health (NIOSH)
  3. Occupational Safety and Health Administration
  4. CDC Childhood Lead Poisoning Prevention Program


Page last reviewed: June 1, 2001 (archived document)
Page last updated: November 2, 2007
Content Source: National Office of Public Health Genomics